Actualités sur Medicale

22.01.2016 – 13:01
Daiichi Sankyo Europe GmbH
German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation
Munich (ots/PRNewswire) - Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced that the German public health agency, The Federal Joint Committee (Gemeinsamer Bundesausschuss - G-BA), has granted an indication of a minor additional benefit for LIXIANA® (edoxaban), an oral, once-daily selective ...
plus
15.01.2016 – 09:01
HOYA Vision Care
HOYA Presents Hoya EyeGenius
Mönchengladbach, Germany (ots/PRNewswire) - The HOYA Vision Care Company, a key player in the global market for ophthalmic lenses, presents Hoya EyeGenius, an innovative high-precision measurement system for the quick and easy measurement and correction of fixation disparities. The digital era demands a lot from our binocular vision and can cause visual stress. In the case of heterophoria, this may lead to fixation disparity. Hoya EyeGenius was developed in close ...
plus
14.01.2016 – 13:01
Accuray Europe
Accuray Announces First Radiation Therapy Systems Installed in Qatar, Latvia and Bulgaria
Sunnyvale, California (ots/PRNewswire) - Premier Qatar, Latvian Cancer Centers to Offer Patients Treatment with the CyberKnife® System; Leading Bulgarian Hospital to Provide Treatment with the TomoTherapy® System Accuray Incorporated (NASDAQ: ARAY) announced today that the first centers in Qatar, Latvia, and Bulgaria are now equipped with its radiation therapy ...
plus
13.01.2016 – 16:01
Debiopharm International SA
Debiopharm International SA and EORTC Announce a Collaboration to Investigate Triptorelin for Treatment of Salivary Gland Cancers
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary gland cancer ...
plus
11.01.2016 – 16:01
Helsinn Healthcare SA
Helsinn Celebrates its 40th Anniversary
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
plus
11.01.2016 – 15:31
Debiopharm International SA
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty
Lausanne, Switzerland and Atlanta (ots/PRNewswire) - Arbor Pharmaceuticals to commercialize triptorelin in sustained-release formulation for the orphan indication central precocious puberty Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, and ...
plus
11.01.2016 – 13:31
Baxalta Incorporated and Shire plc
Shire to Combine with Baxalta, Creating the Global Leader in Rare Diseases
Dublin and Bannockburn, Illinois (ots/PRNewswire) - Combination creates leading global biotechnology company projected to deliver double-digit top-line growth with over $20 billion in annual revenues by 2020 - No. 1 platform in rare diseases expected to generate 65% of total annual revenues - Multiple, durable billion-dollar franchises, each with best-in-class products ...
plus
07.01.2016 – 14:34
ViiV Healthcare
ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection
London (ots/PRNewswire) - ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with Janssen Sciences Ireland UC (Janssen) for the phase III investigation and commercialisation of the long-acting, injectable formulations of ...
plus
07.01.2016 – 14:07
Janssen Sciences Ireland UC
Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable Regimen for Treatment of HIV Infection
Cork, Ireland (ots/PRNewswire) - Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development ...
plus
07.01.2016 – 09:00
BioMed X GmbH
BioMed X announces collaboration with Johnson & Johnson Innovation in the field of oral health research
Heidelberg (ots) - BioMed X Innovation Center announced today that they have entered into a collaboration agreement with Johnson & Johnson Consumer, Inc. seeking to establish a research group to focus on the development of novel methods for the disruption of oral biofilms. This collaboration was facilitated by ...
plus
07.01.2016 – 08:24
Merck Healthcare Germany GmbH
Merck and Biocartis to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing
Darmstadt, Germany (ots/PRNewswire) - - Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing - Collaboration allows Merck to provide complementary molecular testing solutions to various laboratory segments - Biocartis' fully automated Idylla(TM) system will enable more clinics to assess RAS ...
plus
21.12.2015 – 08:01
HOYA Vision Care
HOYA Vision Care Establishes Subsidiary in Russia
Uithoorn, The Netherlands (ots/PRNewswire) - HOYA Vision Care Company, a key player in the global market for ophthalmic lenses, announces the establishment of HOYA Lens RUS LLC. Building on a strong position in the Russian Federation through a longtime local distributor, HOYA is now entering the market directly to provide better service and further develop its customer base. HOYA sees significant opportunities to expand ...
plus
18.12.2015 – 22:01
Janssen Pharmaceutica
Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections
Raritan, New Jersey (ots/PRNewswire) - New approach for early treatment and interception of HPV-induced cancers Janssen Pharmaceuticals, Inc. (Janssen) announced today that the company has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN® technology, ...
plus
14.12.2015 – 11:02
Secofind
Matteo Dante Perruccio Appointed Chairman of Secofind SIM SpA
Milan (ots/PRNewswire) - Matteo Dante Perruccio has been appointed the new Chairman of Secofind SIM SpA, the Multi-Family Office. Founded by the Zambon Family in the mid-90s, originally to manage the family assets but and subsequently offering the same services of advice and risk management to other industrial and entrepreneurial business families. Elena Zambon, Founder, stepped down in July, becoming Honorary Chairman a ...
plus
08.12.2015 – 09:01
Debiopharm International SA
EMA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1143 for treatment of Ovarian Cancer affecting around 154 ...
plus
07.12.2015 – 09:51
Merck Healthcare Germany GmbH
Merck Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Despite signs of activity in locally advanced and metastatic pancreatic cancer, two Phase III studies did not meet pre-specified primary endpoints - Merck will focus efforts on more promising candidates in pipeline Merck, a leading science and ...
plus
07.12.2015 – 09:04
Debiopharm International SA
United Laboratories Inc. and Debiopharm International SA Announce the Launch of Pamorelin® LA in the Philippines
Mandaluyong, Philippines and Lausanne, Switzerland (ots/PRNewswire) - Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines United Laboratories Inc. (Unilab) and Debiopharm International SA (Debiopharm) announce the signature of an exclusive agreement for the distribution ...
plus
03.12.2015 – 13:31
CGI Group Inc.
UK Ministry of Defence Selects CGI to Provide Integrated Electronic Health Record Information Service
London (ots/PRNewswire) - Contract to support up to 6,000 users at 400 sites worldwide for Defence Medical Services, enhancing CGI's existing service, which began in 2006 Stock Market Symbols GIB (NYSE) GIB.A (TSX) http://www.cgi.com/newsroom CGI (NYSE: GIB) (TSX: GIB.A) has been selected to provide an integrated electronic health record (iEHR) service for the UK ...
plus
01.12.2015 – 19:03
Novo Nordisk
Ryzodeg® Delivers Significantly Lower Rates of Hypoglycaemia and Nocturnal Hypoglycaemia in a Broad Range of Type 2 Diabetes Patients
Vancouver, British Columbia (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. Abstracts 0336-P, 0337-P, 0338-P New analyses demonstrate that ...
plus
01.12.2015 – 19:02
Novo Nordisk
New data reveal why physicians and people with type 2 diabetes uncontrolled on basal insulin are reluctant to intensify insulin therapy
Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. Results from the Perceptions of Control (POC) study showed that people with type ...
plus
01.12.2015 – 19:02
Novo Nordisk
New data highlight impact of post-meal hyperglycaemia on people with diabetes
Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. Abstracts: 0720-P, 0721-P, 1074-P, 0956-P New data from four analyses[1],[2],[3],[4] demonstrate that post-meal hyperglycaemia (when ...
plus
01.12.2015 – 19:02
Novo Nordisk
Victoza® (liraglutide) provides greater glycaemic control than SGLT-2 inhibitors
Vancouver, Canada (ots/PRNewswire) - This material is intended for global medical media only. This material is not approved for Canadian journalists or Canadian audiences. For journalistic assessment and preparation before publication. New findings from a network meta-analysis show that treatment with Victoza® (liraglutide) provides a greater HbA1c reduction and an ...
plus
26.11.2015 – 13:17
Accuray Europe
European School of Robotic Stereotactic Radiotherapy Advances With the CyberKnife® M6(TM) System
Sunnyvale, California (ots/PRNewswire) - Erasmus MC Team Hosts Clinicians from Around-the-World at Fully-Subscribed Course Accuray Incorporated (Nasdaq: ARAY) announced the second course of the European School of Robotic Stereotactic Radiotherapy at Erasmus MC Center Institute, Rotterdam, The Netherlands, following ...
plus
24.11.2015 – 09:01
Debiopharm International SA
Debiopharm International SA's Partner Yakult Honsha Co, Ltd. Announces Elplat® Approbation in Gastric Cancer in Japan
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, is proud to congratulate its partner Yakult's commitment in obtaining approval for a supplemental new drug application for Elplat® in postoperative ...
plus
18.11.2015 – 23:06
Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies
New Data Published in the New England Journal of Medicine Shows Potential of Compound to Fight RSV Infection in Adults and Children
San Francisco (ots/PRNewswire) - - ALS-008176 now being evaluated in RSV-infected infants - Alios BioPharma, Inc., part of the Janssen Pharmaceutical Companies announced that the New England Journal of Medicine (NEJM) will publish findings from a respiratory syncytial virus (RSV) challenge study for ALS-008176, a ...
plus
18.11.2015 – 08:32
Aptus Health
Physicians Interactive Becomes Aptus Health, Offering a Global Digital Health Engagement Solution
Reading, Massachusetts (ots/PRNewswire) - Change reflects the company's evolution to a strategic partner, delivering data-driven digital and mobile health engagement campaigns that empower better decisions and drive business results Physicians Interactive today announced that it has become Aptus Health (http://www.aptushealth.com/), reflecting its mission of advancing ...
plus
17.11.2015 – 09:01
Royal Philips
Cookbook for Large Scale Coordinated Care and Telehealth Deployment Debuted by Philips-led European Consortium of Leading Companies, Universities, Hospitals and Healthcare Authorities
Amsterdam (ots/PRNewswire) - - 2.5 year scientific evaluation of European integrated care programs and 2,500 surveys provide unparalleled insights on success factors of connected care programs across the European Union - Advanced Care Coordination and Telehealth Deployment (ACT) program addresses EU's aging ...
plus
16.11.2015 – 15:58
Aegate
Aegate Continues to Demonstrate Expertise in US Falsified Medicine Detection Ahead of DQSA Act Implementation
London and Washington D.c. (ots/PRNewswire) - Aegate, the world's leading provider of medicines authentication services, continues to fulfil its commitment to support all stakeholders in the healthcare value chain in the swift achievement of the Drug Quality and Security Act (DQSA) compliance within the mandated ...
plus
11.11.2015 – 12:03
LEO Pharma
LEO Pharma to Acquire Global Dermatology Portfolio from Astellas
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for EUR 675 million. (Logo: ...
plus
10.11.2015 – 15:16
Novo Nordisk
Victoza® (liraglutide) is cost-effective vs. lixisenatide and cost-saving vs. exenatide in the UK
Milan (ots/PRNewswire) - Abstract: PDB54 B20 New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza® (liraglutide) 1.2 mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide and is cost-saving compared to exenatide.[1] ...
plus

Précédent35363738394041424344Suivant